Blue Water Biotech, Inc. announced an agreement with UpScriptHealth to generate a robust, online telemedicine platform to distribute Blue Water?s benign prostatic hyperplasia asset, ENTADFI. Under this agreement, UpScript will build an online platform to support BPH patients throughout the prescription and coverage process, as well as provide eligible patients access to ENTADFI mailed directly to their homes. UpScript, a leading provider of telehealth services, has over 20 years of experience generating effective, web-based campaigns for life science companies with a wide range of services, including virtual prescribing, coverage and benefit support, as well as long-term adherence support.

It is estimated about 55 million men in the United States have or are at risk for BPH, with affected patients suffering from challenges with urination flow, frequency, and urgency, along with sexual dysfunction in many cases. Through this online platform, existing BPH patients will be able to communicate with a healthcare provider online and may be eligible to receive ENTADFI without the need for another specialist visit and can receive their prescription in the mail or through one of UpScript?s partner pharmacies. This solution will be designed to not only increase access for ENTADFI nationwide, but also offers patients a time-saving solution while still receiving administrative help during the coverage process through UpScript?s benefit support capabilities.

This agreement with UpScript represents a milestone reached by Blue Water in its efforts to launch its commercial portfolio, highlighted by ENTADFI, that was previously announced in a letter to shareholders from Mr. Hernandez earlier this month. With the official launch of ENTADFI scheduled in the coming months, Blue Water?s commercial team is executing on key strategies including sales force development, distribution capabilities, as well as marketing and advertising development.